The emergence of Retatrutide ZPHC, at a strength of 120mg, is sparking considerable interest within the medical community. This novel dual GIP and GLP-1 agonist medication appears to offer significant improvements in weight loss compared to current therapies. Early clinical trials have indicated substantial reductions in body mass , possibly signif